Helen J Lachmann

List of Publications by Year
in descending order

266	24,030	5891	8156
papers	citations	81 h-index	148 g-index

273	273	273	14614
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
2	Natural History and Outcome in Systemic AA Amyloidosis. New England Journal of Medicine, 2007, 356, 2361-2371.	13.9	817
3	Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. New England Journal of Medicine, 2009, 360, 2416-2425.	13.9	754
4	Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis and Rheumatism, 2004, 50, 607-612.	6.7	731
5	Interleukin-1â€“Receptor Antagonist in the Muckleâ€“Wells Syndrome. New England Journal of Medicine, 2003, 348, 2583-2584.	13.9	636
6	Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis. New England Journal of Medicine, 2002, 346, 1786-1791.	13.9	621
7	Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. New England Journal of Medicine, 2020, 383, 2628-2638.	13.9	580
8	Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature, 2002, 417, 254-259.	13.7	495
9	Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation, 2015, 132, 1570-1579.	1.6	442
10	A new staging system for cardiac transthyretin amyloidosis. European Heart Journal, 2018, 39, 2799-2806.	1.0	396
11	T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 ⁺ T cells. Science, 2016, 352, aad1210.	6.0	395
12	The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the ClinicalÂDiagnosis of Inborn Errors of Immunity. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1763-1770.	2.0	381
13	Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. British Journal of Haematology, 2003, 122, 78-84.	1.2	370
14	Association of mutations in theNALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis and Rheumatism, 2002, 46, 2445-2452.	6.7	350
15	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases, 2013, 72, 678-685.	0.5	350
16	Native T1 Mapping in Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 157-165.	2.3	339
17	A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood, 2015, 126, 612-615.	0.6	334
18	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	4.1	330

#	Article	IF	Citations
19	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919.	13.9	327
20	T1 mapping and survival in systemic light-chain amyloidosis. European Heart Journal, 2015, 36, 244-251.	1.0	310
21	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.5	300
22	Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation, 2019, 140, 16-26.	1.6	288
23	Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome. Journal of the American Heart Association, 2013, 2, e000098.	1.6	275
24	In vivo regulation of interleukin 1Î² in patients with cryopyrin-associated periodic syndromes. Journal of Experimental Medicine, 2009, 206, 1029-1036.	4.2	270
25	Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. Journal of Clinical Investigation, 2015, 125, 4196-4211.	3.9	258
26	The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Annals of the Rheumatic Diseases, 2014, 73, 2160-2167.	0.5	256
27	Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood, 2012, 119, 4387-4390.	0.6	250
28	CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 133-142.	2.3	242
29	Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. New England Journal of Medicine, 2007, 356, 2349-2360.	13.9	240
30	Recommendations for the management of autoinflammatory diseases. Annals of the Rheumatic Diseases, 2015, 74, 1636-1644.	0.5	239
31	The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nature Reviews Nephrology, 2012, 8, 43-51.	4.1	226
32	Schnitzler's syndrome: diagnosis, treatment, and followâ€up. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 562-568.	2.7	224
33	Systemic Amyloidosis in <scp>E</scp>ngland: an epidemiological study. British Journal of Haematology, 2013, 161, 525-532.	1.2	222
34	Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations. Human Mutation, 2014, 35, E2403-E2412.	1.1	220
35	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.5	215
36	Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood, 2007, 109, 457-464.	0.6	212

#	Article	IF	Citations
37	Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. European Heart Journal Cardiovascular Imaging, 2014, 15, 1289-1298.	0.5	184
38	Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Annals of the Rheumatic Diseases, 2011, 70, 2095-2102.	0.5	182
39	Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Annals of the Rheumatic Diseases, 2015, 74, 2043-2049.	0.5	180
40	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Annals of the Rheumatic Diseases, 2017, 76, 942-947.	0.5	175
41	Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis and Rheumatism, 2003, 48, 2632-2644.	6.7	173
42	Phenotype, Genotype, and Sustained Response to Anakinra in 22 Patients With Autoinflammatory Disease Associated With CIAS-1/NALP3 Mutations. Archives of Dermatology, 2006, 142, 1591-7.	1.7	168
43	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis and Rheumatology, 2016, 68, 2795-2805.	2.9	168
44	An International registry on Autoinflammatory diseases: the Eurofever experience. Annals of the Rheumatic Diseases, 2012, 71, 1177-1182.	0.5	158
45	Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Radiology, 2015, 277, 388-397.	3.6	146
46	Diagnosis, Pathogenesis, Treatment, and Prognosis of Hereditary Fibrinogen AÎ±-Chain Amyloidosis. Journal of the American Society of Nephrology: JASN, 2009, 20, 444-451.	3.0	145
47	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2015, 74, 635-641.	0.5	145
48	Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. European Heart Journal, 2017, 38, 1905-1908.	1.0	144
49	Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. European Heart Journal, 2012, 33, 1120-1127.	1.0	143
50	Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 230.	3.8	139
51	A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood, 2019, 134, 2271-2280.	0.6	130
52	A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. European Heart Journal, 2015, 36, 1098-1105.	1.0	129
53	Outcome in Renal AL Amyloidosis After Chemotherapy. Journal of Clinical Oncology, 2011, 29, 674-681.	0.8	126
54	Noncontrast Magnetic Resonance for theÂDiagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 69-80.	2.3	125

#	Article	IF	Citations
55	Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. European Heart Journal Cardiovascular Imaging, 2017, 18, 1344-1350.	0.5	124
56	Guidelines on the diagnosis and investigation of AL amyloidosis. British Journal of Haematology, 2015, 168, 207-218.	1.2	122
57	Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis and Rheumatism, 2002, 46, 2571-2573.	6.7	121
58	Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrology Dialysis Transplantation, 2008, 24, 676-678.	0.4	121
59	Secondary, AA, Amyloidosis. Rheumatic Disease Clinics of North America, 2018, 44, 585-603.	0.8	121
60	Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. Annals of the Rheumatic Diseases, 2014, 73, 2168-2173.	0.5	120
61	Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica, 2008, 93, 295-298.	1.7	115
62	Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Annals of the Rheumatic Diseases, 2018, 77, 1558-1565.	0.5	114
63	Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 2006, 107, 1227-1229.	0.6	113
64	Cardiac Structural and Functional Consequences of Amyloid Deposition byÂCardiac Magnetic Resonance andÂEchocardiography and TheirÂPrognosticÂRoles. JACC: Cardiovascular Imaging, 2019, 12, 823-833.	2.3	113
65	Guidelines on the management of <scp>AL</scp> amyloidosis. British Journal of Haematology, 2015, 168, 186-206.	1.2	112
66	Amyloidogenicity and Clinical Phenotype Associated with Five Novel Mutations in Apolipoprotein A-I. American Journal of Pathology, 2011, 179, 1978-1987.	1.9	111
67	Solid Organ Transplantation in AL Amyloidosis. American Journal of Transplantation, 2010, 10, 2124-2131.	2.6	109
68	Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicismâ€”UK Single Center Experience. Frontiers in Immunology, 2017, 8, 1410.	2.2	109
69	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. European Heart Journal, 2020, 41, 1439-1447.	1.0	108
70	Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. British Journal of Haematology, 2010, 148, 760-767.	1.2	106
71	Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Research and Therapy, 2011, 13, R202.	1.6	106
72	Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. Lancet Haematology,the, 2015, 2, e241-e250.	2.2	105

#	Article	IF	Citations
73	Natural history and outcome of light chain deposition disease. Blood, 2015, 126, 2805-2810.	0.6	103
74	Systemic amyloidosis. Current Opinion in Pharmacology, 2006, 6, 214-220.	1.7	102
75	MEFVmutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Annals of the Rheumatic Diseases, 2014, 73, 455-461.	0.5	101
76	Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Annals of the Rheumatic Diseases, 2017, 76, 173-178.	0.5	96
77	A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. Journal of Clinical Pathology, 2015, 68, 314-317.	1.0	95
78	Brief Report: AA Amyloidosis Complicating the Hereditary Periodic Fever Syndromes. Arthritis and Rheumatism, 2013, 65, 1116-1121.	6.7	90
79	CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. JACC: Cardiovascular Imaging, 2018, 11, 152-154.	2.3	90
80	A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia, 2014, 28, 2304-2310.	3.3	89
81	Improvement in renal cholesterol emboli syndrome after simvastatin. Lancet, The, 1998, 351, 1331-1332.	6.3	87
82	Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. British Journal of Haematology, 2006, 134, 417-425.	1.2	84
83	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology, 2017, 56, 2102-2108.	0.9	84
84	Periodic fever syndromes. Best Practice and Research in Clinical Rheumatology, 2017, 31, 596-609.	1.4	84
85	Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. Blood, 2018, 131, 974-981.	0.6	83
86	The emerging role of interleukinâ€1Î² in autoinflammatory diseases. Arthritis and Rheumatism, 2011, 63, 314-324.	6.7	82
87	Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis. American Journal of Transplantation, 2006, 6, 2342-2347.	2.6	76
88	International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptorâ€"Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care and Research, 2017, 69, 578-586.	1.5	75
89	Complement receptor CD46 co-stimulates optimal human CD8+ T cell effector function via fatty acid metabolism. Nature Communications, 2018, 9, 4186.	5.8	75
90	How not to miss autoinflammatory diseases masquerading as urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1465-1474.	2.7	74

#	Article	IF	Citations
91	Renal Transplantation in Systemic Amyloidosisâ€"Importance of Amyloid Fibril Type and Precursor Protein Abundance. American Journal of Transplantation, 2013, 13, 433-441.	2.6	74
92	AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood, 2008, 112, 4009-4016.	0.6	73
93	Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology, 2010, 74, 1267-1270.	1.5	72
94	A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Annals of the Rheumatic Diseases, 2011, 70, 309-314.	0.5	70
95	Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turkish Journal of Medical Sciences, 2020, 50, 1591-1610.	0.4	70
96	Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Annals of the Rheumatic Diseases, 2012, 71, 2035-2043.	0.5	69
97	Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis. PLoS ONE, 2017, 12, e0181874.	1.1	69
98	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.5	68
99	Clinical Importance of Left Atrial Infiltration in Cardiac TransthyretinÂAmyloidosis. JACC: Cardiovascular Imaging, 2022, 15, 17-29.	2.3	67
100	Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. British Journal of Haematology, 2002, 117, 427-435.	1.2	65
101	IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis. Journal of Investigative Dermatology, 2020, 140, 816-826.e3.	0.3	64
102	Infusion of Pharmaceutical-Grade Natural Human C-Reactive Protein Is Not Proinflammatory in Healthy Adult Human Volunteers. Circulation Research, 2014, 114, 672-676.	2.0	63
103	Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 162-166.	1.4	61
104	European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin Mâ€"Related Light Chain Amyloidosis. Journal of Clinical Oncology, 2016, 34, 2037-2045.	0.8	60
105	Hereditary lysozyme amyloidosis â€" phenotypic heterogeneity and the role of solid organ transplantation. Journal of Internal Medicine, 2012, 272, 36-44.	2.7	59
106	Amyloidosis and the lung. Chronic Respiratory Disease, 2006, 3, 203-214.	1.0	58
107	Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes and Immunity, 2004, 5, 289-293.	2.2	53
108	Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature. Arthritis Research and Therapy, 2013, 15, R30.	1.6	53

#	Article	IF	Citations
109	Performance of Different Diagnostic Criteria for Familial Mediterranean Fever in Children with Periodic Fevers: Results from a Multicenter International Registry. Journal of Rheumatology, 2016, 43, 154-160.	1.0	52
110	A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet Journal of Rare Diseases, 2017, 12, 167.	1.2	52
111	AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: A report of two cases. Arthritis and Rheumatism, 2006, 54, 2010-2014.	6.7	50
112	Brief Report: Association of Tumor Necrosis Factor Receptorâ€"Associated Periodic Syndrome With Gonosomal Mosaicism of a Novel 24â€Nucleotide TNFRSF1A Deletion. Arthritis and Rheumatology, 2016, 68, 2044-2049.	2.9	49
113	Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residueâ€"a case series and genetic exploration. Rheumatology, 2017, 56, 209-213.	0.9	49
114	Lenalidomide and dexamethasone for systemic <scp>AL</scp> amyloidosis following prior treatment with thalidomide or bortezomib regimens. British Journal of Haematology, 2014, 166, 842-848.	1.2	47
115	Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate. Nature Communications, 2020, 11, 3412.	5.8	47
116	The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. Journal of Pathology: Clinical Research, 2019, 5, 145-153.	1.3	46
117	Brief Report: Wholeâ€Exome Sequencing Revealing Somatic NLRP3 Mosaicism in a Patient With Chronic Infantile Neurologic, Cutaneous, Articular Syndrome. Arthritis and Rheumatology, 2014, 66, 197-202.	2.9	44
118	Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis. Haematologica, 2018, 103, e165-e168.	1.7	44
119	ISSAID/EMQN Best Practice Guidelines for the Genetic Diagnosis of Monogenic Autoinflammatory Diseases in the Next-Generation Sequencing Era. Clinical Chemistry, 2020, 66, 525-536.	1.5	43
120	The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. American Heart Journal, 2012, 164, 72-79.	1.2	41
121	The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Annals of the Rheumatic Diseases, 2022, 81, 907-921.	0.5	38
122	Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. Rheumatology, 2014, 53, 665-670.	0.9	35
123	The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey. Pediatric Rheumatology, 2018, 16, 19.	0.9	35
124	Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. British Journal of Haematology, 2019, 187, 638-641.	1.2	35
125	Developments in the scientific and clinical understanding of autoinflammatory disorders. Arthritis Research and Therapy, 2009, 11, 212.	1.6	34
126	Rapid and Sustained Longâ€Term Efficacy and Safety of Canakinumab in Patients With Cryopyrinâ€Associated Periodic Syndrome Ages Five Years and Younger. Arthritis and Rheumatology, 2019, 71, 1955-1963.	2.9	34

#	Article	IF	Citations
127	Exploratory Study of <scp>MYD</scp>88 L265P, Rare <scp>NLRP</scp>3 Variants, and Clonal Hematopoiesis Prevalence in Patients With Schnitzler Syndrome. Arthritis and Rheumatology, 2019, 71, 2121-2125.	2.9	33
128	Systemic AA Amyloidosis. Sub-Cellular Biochemistry, 2012, 65, 541-564.	1.0	32
129	Inflammatory Bowel Disease and Systemic AA Amyloidosis. Digestive Diseases and Sciences, 2013, 58, 1689-1697.	1.1	32
130	Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis. Haematologica, 2011, 96, 1079-1080.	1.7	31
131	Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. Annals of the Rheumatic Diseases, 2017, 76, 303-309.	0.5	30
132	A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. Journal of Cardiology Cases, 2011, 4, e93-e97.	0.2	29
133	The Emerging Role of Interleukin-1Î² in Autoinflammatory Diseases. Current Allergy and Asthma Reports, 2011, 11, 361-368.	2.4	29
134	A 24â€year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom. British Journal of Haematology, 2019, 187, 642-652.	1.2	29
135	Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Human Mutation, 2019, 40, 90-96.	1.1	29
136	Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology, 2021, 60, 3799-3808.	0.9	29
137	Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. Clinical and Experimental Rheumatology, 2015, 33, S46-53.	0.4	29
138	A prospective study of nutritional status in immunoglobulin light chain amyloidosis. Haematologica, 2013, 98, 136-140.	1.7	27
139	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.5	27
140	Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. European Heart Journal, 2022, 43, 2622-2632.	1.0	27
141	99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2021, 22, 1304-1311.	0.5	26
142	ALchemy - A Large Prospective â€˜Real World' Study of Chemotherapy in AL Amyloidosis. Blood, 2011, 118, 992-992.	0.6	26
143	Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. European Journal of Heart Failure, 2022, 24, 1700-1712.	2.9	26
144	Emerging treatments for amyloidosis. Kidney International, 2015, 87, 516-526.	2.6	25

#	Article	IF	Citations
145	Renal Amyloidosis Associated With 5 NovelÂVariants in the Fibrinogen A Alpha Chain Protein. Kidney International Reports, 2017, 2, 461-469.	0.4	25
146	Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine. Blood, 2018, 132, 761-764.	0.6	25
147	Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid lightâ€chain amyloidosis. British Journal of Haematology, 2020, 189, 643-649.	1.2	25
148	Two types of amyloid in a single heart. Blood, 2014, 124, 3025-3027.	0.6	24
149	Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reductionÂisÂthe crucial factor. Kidney International, 2017, 92, 1476-1483.	2.6	22
150	Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System. Current Treatment Options in Neurology, 2018, 20, 43.	0.7	22
151	Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Failure, 2020, 7, 3942-3949.	1.4	22
152	Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2004, 11, 44-49.	1.4	20
153	Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis. British Journal of Haematology, 2018, 182, 145-148.	1.2	20
154	Renal transplant outcomes in amyloidosis. Nephrology Dialysis Transplantation, 2021, 36, 355-365.	0.4	20
155	Cardiac Magnetic Resonanceâ€“Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. Circulation: Cardiovascular Imaging, 2021, 14, CIRCIMAGING121012506.	1.3	19
156	Hypercalcemia in a Patient With Common Variable Immunodeficiency and Renal Granulomas. American Journal of Kidney Diseases, 2005, 45, e90-e93.	2.1	18
157	Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis. Nephrology Dialysis Transplantation, 2016, 33, gfw375.	0.4	18
158	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. JAMA Dermatology, 2020, 156, 1216.	2.0	18
159	One Hundred Cases of Localized Laryngeal Amyloidosis â€•Evidence for Future Management. Laryngoscope, 2021, 131, E1912-E1917.	1.1	18
160	Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 128-133.	3.3	17
161	Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 189-193.	1.4	17
162	Hereditary fibrinogen A Î±-chain amyloidosis: clinical phenotype and role of liver transplantation. Blood, 2010, 115, 4313-4313.	0.6	16

#	Article	IF	Citations
163	Immunoparesis defined by heavy+light chain suppression is a novel marker of longâ€term outcomes in cardiac AL amyloidosis. British Journal of Haematology, 2017, 179, 575-585.	1.2	16
164	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptorâ€“associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	1.0	16
165	INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 783-791.e4.	2.0	16
166	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. Trials, 2018, 19, 465.	0.7	15
167	Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis. British Journal of Haematology, 2018, 183, 557-563.	1.2	15
168	Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers. British Journal of Haematology, 2019, 186, 460-470.	1.2	15
169	COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics. Rheumatology Advances in Practice, 2021, 5, rkab043.	0.3	15
170	Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib. Blood Cancer Journal, 2021, 11, 118.	2.8	15
171	Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinflammatory Diseases at a National Referral Center. Journal of the American Heart Association, 2022, 11, .	1.6	15
172	Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting. Haematologica, 2014, 99, e260-e263.	1.7	14
173	Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis. Haematologica, 2015, 100, 1469-1476.	1.7	14
174	Autoinflammatory Syndromes in Children. Indian Journal of Pediatrics, 2016, 83, 242-247.	0.3	14
175	The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukinâ€1 Mediated Autoinflammatory Diseases: Cryopyrinâ€Associated Periodic Syndromes, Tumour Necrosis Factor Receptorâ€Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukinâ€1 Receptor Antagonist. Arthritis and Rheumatology, 2022, 74, 1102-1121.	2.9	14
176	Autoinflammatory syndromes as causes of fever of unknown origin. Clinical Medicine, 2015, 15, 295-298.	0.8	13
177	Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis â€“ Results From the UK Amyloidosis Treatment Trial.. Blood, 2009, 114, 2869-2869.	0.6	13
178	Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 200-205.	1.4	12
179	Novel Pharmacological Strategies in Amyloidosis. Nephron Clinical Practice, 2003, 94, c85-c88.	2.3	11
180	Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report.. Blood, 2006, 108, 129-129.	0.6	11

#	Article	IF	Citations
181	Familial Mediterranean fever caused by homozygous E148Q mutation complicated by Budd-Chiari syndrome and polyarteritis nodosa. Rheumatology, 2011, 50, 624-626.	0.9	10
182	A New Era in the Treatment of Amyloidosis?. New England Journal of Medicine, 2013, 369, 866-868.	13.9	10
183	The value of screening biopsies in lightâ€chain (AL) and transthyretin (ATTR) amyloidosis. European Journal of Haematology, 2020, 105, 352-356.	1.1	10
184	Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria. Haematologica, 2020, 105, 1405-1413.	1.7	10
185	Reply to: Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis. Dinoia et al. Clinical and Experimental Rheumatology, 2017, 35, 171.	0.4	10
186	Renal amyloidosis. British Journal of Hospital Medicine (London, England: 2005), 2010, 71, 83-86.	0.2	9
187	TRAP1 chaperone protein mutations and autoinflammation. Life Science Alliance, 2020, 3, e201900376.	1.3	9
188	Comparison of Free Light Chain Assays. American Journal of Clinical Pathology, 2016, 146, 78-85.	0.4	8
189	British kindred with dominant FMF associated with high incidence of AA amyloidosis caused by novel MEFV variant, and a review of the literature. Rheumatology, 2020, 59, 554-558.	0.9	8
190	Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart, 2022, 108, 474-478.	1.2	8
191	Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis. Journal of Cardiovascular Magnetic Resonance, 2012, 14, .	1.6	7
192	Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature. CEN Case Reports, 2014, 3, 68-74.	0.5	7
193	When is familial Mediterranean fever 'severe'?. Nature Reviews Rheumatology, 2016, 12, 256-258.	3.5	7
194	Tocilizumab for the Treatment of Mevalonate Kinase Deficiency. Case Reports in Pediatrics, 2018, 2018, 1-6.	0.2	7
195	How to prescribe a genetic test for the diagnosis of autoinflammatory diseases?. Presse Medicale, 2019, 48, e49-e59.	0.8	7
196	Amyloidosis Diagnosed in Solid Organ Transplant Recipients. Transplantation, 2020, 104, 415-420.	0.5	7
197	The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis. Blood Cancer Journal, 2020, 10, 60.	2.8	7
198	Intermediate Dose Intravenous Melphalan and Dexamethasone Treatment in 144 Patients with Systemic AL Amyloidosis.. Blood, 2004, 104, 755-755.	0.6	7

#	Article	IF	Citations
199	Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. Blood, 2008, 112, 1689-1689.	0.6	7
200	A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. Trials, 2020, 21, 158.	0.7	7
201	An unusual phenotype in Muckle-Wells syndrome associated with NLRP3 E311K. Rheumatology, 2011, 50, 419-420.	0.9	6
202	Evidence of B Cell Clonality and Investigation Into Properties of the IgM in Patients With Schnitzler Syndrome. Frontiers in Immunology, 2020, 11, 569006.	2.2	6
203	Two types of systemic amyloidosis in a single patient. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 275-276.	1.4	6
204	A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP.. Blood, 2009, 114, 2796-2796.	0.6	6
205	In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.. Blood, 2009, 114, 745-745.	0.6	6
206	Clinical characteristics and SAP scintigraphic findings in 10 patients with AGel amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 276-281.	1.4	5
207	Trapped without a diagnosis: Tumour necrosis factor receptor-associated periodic syndrome (TRAPS). Practical Neurology, 2016, 16, 304-307.	0.5	5
208	High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. Sleep Medicine, 2017, 32, 191-197.	0.8	5
209	Carpal Tunnel Biopsy Identifying Transthyretin Amyloidosis. Arthritis and Rheumatology, 2017, 69, 2051-2051.	2.9	5
210	Muckleâ€Wells syndrome: a rare hereditary cryopyrinâ€associated periodic syndrome. International Journal of Rheumatic Diseases, 2017, 20, 1873-1875.	0.9	5
211	Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome. Pediatric Rheumatology, 2019, 17, 36.	0.9	5
212	Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic <scp>AL</scp> amyloidosis. British Journal of Haematology, 2019, 185, 977-980.	1.2	5
213	Cardiovascular disease risk assessment in patients with familial Mediterranean fever related renal amyloidosis. Scientific Reports, 2020, 10, 18374.	1.6	5
214	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. Blood, 2021, 138, 2721-2721.	0.6	5
215	The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 237-244.	1.4	5
216	A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 26-30.	1.4	4

#	Article	IF	Citations
217	Response to Letters Regarding Article, â€œPrognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosisâ€. Circulation, 2016, 133, e450-1.	1.6	4
218	Autologous stem cell transplantation vs bortezomib based chemotheraphy for the firstâ€line treatment of systemic light chain amyloidosis in the UK. European Journal of Haematology, 2021, 106, 537-545.	1.1	4
219	Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of realâ€world longitudinal data. British Journal of Haematology, 2021, 194, 587-597.	1.2	4
220	Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment.. Blood, 2009, 114, 1791-1791.	0.6	4
221	A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 72-73.	1.4	3
222	Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting as transfusion-dependent refractory haemophagocytosis. Rheumatology, 2018, 57, 582-583.	0.9	3
223	Successful treatment of systemic AA amyloidosis associated with underlying Hodgkin lymphoma. British Journal of Haematology, 2018, 182, 619-619.	1.2	3
224	Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin lightâ€chain (AL) amyloidosis. British Journal of Haematology, 2021, 194, 1016-1023.	1.2	3
225	Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.. Blood, 2008, 112, 1733-1733.	0.6	3
226	IL-1 Inhibition in Cryopyrin-Associated Periodic Syndrome and Beyond: A Million Dollar Question about the Injection Schedule of Biotherapies. Dermatology, 2011, 223, 119-121.	0.9	2
227	Pitfalls in conducting prospective trials in stage III cardiac amyloidosis â€“ experience from the REVEAL study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 250-252.	1.4	2
228	Secondary, AA, Amyloidosis. , 2010, , 179-189.		2
229	Standard Oral Melphalan Chemotherapy for AL Amyloidosis Revisited Using the Serum Free Light Chain Assay.. Blood, 2005, 106, 3495-3495.	0.6	2
230	A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.. Blood, 2012, 120, 2966-2966.	0.6	2
231	The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis. Blood, 2020, 136, 16-17.	0.6	2
232	A <scp>UK</scp> consensus algorithm for early treatment modification in newly diagnosed systemic lightâ€chain amyloidosis. British Journal of Haematology, 2022, , .	1.2	2
233	Paraprotein-related renal disease and amyloid. Medicine, 2007, 35, 512-515.	0.2	1
234	Clinical profile and treatment outcomes of immunoglobulin <scp>D</scp> associated <scp>AL</scp> amyloidosis. British Journal of Haematology, 2013, 162, 856-858.	1.2	1

#	Article	IF	Citations
235	Long-Term Complications of Familial Mediterranean Fever. Rare Diseases of the Immune System, 2015, , 91-105.	0.1	1
236	Paraprotein-related renal disease and amyloid. Medicine, 2015, 43, 533-537.	0.2	1
237	A baffling case of severe systemic inflammation. Putting the pieces together: genes, environment and triggers. Rheumatology, 2017, 56, 853-854.	0.9	1
238	The Authors Reply:. JACC: Cardiovascular Imaging, 2020, 13, 1294-1295.	2.3	1
239	Autoinflammatory Disorders. , 2017, , 393-435.		1
240	The Prognostic Significance of Phenotypically â€˜Normalâ€™ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma. Blood, 2014, 124, 2073-2073.	0.6	1
241	Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,. Blood, 2011, 118, 3975-3975.	0.6	1
242	Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,. Blood, 2011, 118, 3978-3978.	0.6	1
243	Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis. Blood, 2012, 120, 4074-4074.	0.6	1
244	The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis. Blood, 2020, 136, 40-40.	0.6	1
245	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. Efficacy and Mechanism Evaluation, 2022, 9, 1-106.	0.9	1
246	Paraprotein-related renal disease and amyloid. Medicine, 2011, 39, 481-485.	0.2	0
247	The Role of Immunological Assessment in Patients With Acute Kidney Injury and Possible Myeloma. Advances in Chronic Kidney Disease, 2012, 19, 287-290.	0.6	0
248	054â€ƒAdult Periodic Fevers, Apthous Ulceration, Pharyngitis and Adenitis: A Single-Centre Experience. Rheumatology, 2016, , .	0.9	0
249	Non-Hodgkin's lymphoma causing light-chain (AL) amyloidosis. British Journal of Hospital Medicine (London, England: 2005), 2016, 77, 188-189.	0.2	0
250	008â€…Demonstration of cardiac AL amyloidosis regression after succesful chemotherapy. a CMR study. Heart, 2017, 103, A7.1-A7.	1.2	0
251	i112â€ƒAuto-inflammatory diseases. Rheumatology, 2018, 57, .	0.9	0
252	Paraprotein-related renal disease. Medicine, 2019, 47, 666-671.	0.2	0

#	Article	IF	Citations
253	Corticosteroid, Other Biologic and Small Molecule Therapies in Systemic Autoinflammatory Disorders. , 2019, , 775-791.		0
254	OP0254â€…CANAKINUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RECURRENT FEVER SYNDROMES: RESULTS FROM A PHASE 3 TRIAL (CLUSTER). , 2019, , .		0
255	OP0258â€…LESSON FROM EUROFEVER REGISTRY AFTER THE FIRST TEN YEARS OF ENROLLMENT. , 2019, , .		0
256	Visual loss with chronic meningeal and systemic inflammation. Practical Neurology, 0, , practneurol-2021-003066.	0.5	0
257	Impact of Chromosomal Abnormalities Revealed by Interphase FISH on Survival in Primary Light Chain Amyloidosis.. Blood, 2004, 104, 4875-4875.	0.6	0
258	Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave.. Blood, 2009, 114, 2814-2814.	0.6	0
259	Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.. Blood, 2009, 114, 1863-1863.	0.6	0
260	Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases. Blood, 2010, 116, 3958-3958.	0.6	0
261	Treatment of Inflammasome-Related Disorders. , 2011, , 209-220.		0
262	Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.. Blood, 2012, 120, 2978-2978.	0.6	0
263	A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra. Journal of Health Economics and Outcomes Research, 2013, 1, 123-133.	0.6	0
264	Amyloidosis and the Respiratory Tract. , 2015, , 91-111.		0
265	Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS). Rare Diseases of the Immune System, 2020, , 235-245.	0.1	0
266	The UK Experience of Renal Transplantation in AL Amyloidosis. Blood, 2019, 134, 2206-2206.	0.6	0